Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6 mg/kg of recombinant tissue-type plasminogen activator. Case reports

J Neurol Sci. 2018 Oct 15:393:24-26. doi: 10.1016/j.jns.2018.07.003. Epub 2018 Jul 7.

Authors

Massimiliano Plastino¹, Domenico Bosco², Laura Giofrè¹, Dario Cristiano¹, Franco Galati³, Paolo Postorino³, Arturo Consoli⁴, Antonietta Fava⁵, Domenico Consoli³

Affiliations

¹ Department of Neuroscience, "S. Giovanni di Dio" Hospital, 88900 Crotone, Italy.
² Department of Neuroscience, "S. Giovanni di Dio" Hospital, 88900 Crotone, Italy. Electronic address: strokeunit@pec.asp.crotone.it.
³ Department of Neuroscience, "Jazzolino" Hospital, Vibo Valentia, Italy.
⁴ Inteventional Neuroradiologist Hôpital Foch, Suresnes, Parigi, France.
⁵ Department of Experimental Medicine, University of Catanzaro, Italy.

PMID: 30098500
DOI: 10.1016/j.jns.2018.07.003

No abstract available

Keywords: Alteplase; Ischemic stroke; New oral anticoagulants.

Publication types

Case Reports
Letter

MeSH terms

Administration, Intravenous
Administration, Oral
Aged
Anticoagulants / therapeutic use*
Atrial Fibrillation / complications
Atrial Fibrillation / drug therapy
Brain Ischemia / complications
Brain Ischemia / drug therapy*
Female
Humans
Male
Recombinant Proteins / therapeutic use
Stroke / complications
Stroke / drug therapy*
Thrombolytic Therapy
Tissue Plasminogen Activator / therapeutic use*

Substances

Anticoagulants
Recombinant Proteins
Tissue Plasminogen Activator